Manjappa Mahadevappa

Manjappa Mahadevappa

Auto-generated profile, based on publicly available information

Manjappa Mahadevappa

Department of Cardiology, JSS Medical College and Hospital, Mysuru JSSAHER, Mysuru, Karnataka, 570004, India

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 May 2022 in Current Cardiology Reviews
Verified
Journal Article
Open access
PDF file
PKPrashanth Kulkarni
Prashanth Kulkarni
MMManjappa Mahadevappa
Manjappa Mahadevappa
SCSrikar Chilakamarri
Srikar Chilakamarri
: Artificial intelligence technology is emerging as a promising entity in cardiovascular medicine, potentially improving diagnosis and patient care. In this article, we review the literature on artificial intelligence and its utility in cardiology. We provide a detailed description of concepts of artificial intelligence tools like machine learning, deep learning, and cognitive computing. This review discusses the current evidence, application, prospects, and limitations of artificial intelligence in cardiology.

10 September 2020 in Current Cardiology Reviews
Verified
Journal Article
Open access
PDF file
PKPrashanth Kulkarni
Prashanth Kulkarni
MMManjappa Mahadevappa
Manjappa Mahadevappa
SASrinivas Alluri
Srinivas Alluri
: The COVID-19 pandemic has emerged as a serious global threat causing a large number of fatalities and putting enormous strain on the health care resources across the world. This has resulted in preferentially triaging the coronavirus infected patients and placing others, especially cardiovascular patients at increased risk for adverse complications. The effective management of cardiac patients in the hospital environment during this COVID-19 pandemic has emerged as a real challenge. We try to address this issue and also highlight the interplay between COVID-19 and cardiovascular diseases. We hereby review the available literature and emerging guidelines about cardiovascular implications related to COVID-19 which will have a bearing on the patient care, health care professionals and cardiac centres.

24 October 2024 in Hospital Pharmacy
Verified
Journal Article
Closed access
MMManjappa Mahadevappa
Manjappa Mahadevappa
SHSakeer Hussain
Sakeer Hussain
SJShivananda Manohar J
Shivananda Manohar J
Donepezil and memantine are second-generation antipsychotics widely used in the management of mild to moderate Alzheimer’s disease. These drugs are highly selective for the central nervous system, targeting different neural pathways to mitigate cognitive decline. Donepezil is a reversible and specific acetylcholinesterase inhibitor, while memantine is an NMDA receptor antagonist which modulates glutamatergic activity. Although these medications are safe, they are associated with adverse effects, and cardiovascular complications are rare. The reported cardiac adverse drug reactions include bradycardia, atrioventricular block, and prolonged QT interval. We are reporting a case of an 81-year-old male patient with schizophrenia, Alzheimer’s disease and bilateral sensorineural deafness receiving oral donepezil and memantine presented with second-degree atrioventricular block. The patient’s atrioventricular block recovered completely in 2 to 3 weeks after the discontinuation of donepezil-memantine and with a short course of sympathomimetic drugs.

1 July 2022 in Indian Journal of Medical Research
Verified
Journal Article
Open access
MMManjappa Mahadevappa
Manjappa Mahadevappa
CMChinmay Meher
Chinmay Meher
NPN.B. Pushpa
N.B. Pushpa
PKPrashanth Kulkarni
Prashanth Kulkarni
KPK.S. Poornima
K.S. Poornima
NDNagaraj Desai
Nagaraj Desai
Background & objectives: With the availability of a wide range of drugs to treat patients with acute coronary syndrome (ACS), adverse drug reactions (ADRs) have become inevitable in clinical practice. Thorough knowledge of such reactions is essential for the treating physician for optimal treatment and better outcomes. There are many scales to define, measure and assess the ADRs, but there is a dearth of data available on such drug reactions among ACS patients. Hence, this study attempted to analyze the pattern, causality, severity, predictability and preventability of ADRs in ACS patients. All the ADRs reported during the study period were analyzed for causality by the World Health Organization–Uppsala Monitoring Centre (WHO-UMC), Naranjo’s and Karch and Lasagna scales; severity by modified Hartwig and Siegel scale; predictability by Rawlins and Thompson criterion and preventability by Schumock and Thornton scale. Methods: A single-centre, record-based analysis for the occurrence of ADRs was done among ACS patients admitted to the department of Cardiology between January and October 2017. Demographic data, comorbid conditions, reported ADRs and ADR assessment details were noted from the hospital case records and ADR monitoring centre (AMC) records. The data were analyzed and presented in a descriptive manner using percentages, mean and standard deviation. The Pearson’s chi-squared test was used to ascertain the significance of the association between different groups. Results: Out of 324 patients under evaluation, 67 had developed one or more ADRs. There were 30 different types of ADRs reported, headache being the most common. Among the drugs, heparin was the most common factor, causing 27 per cent of ADRs. Definite causality of a suspected drug causing ADRs was seen in 11.9 (n=8), nine (n=6) and 7.5 (n=5) per cent cases as per WHO-UMC, Naranjo (Naranjo algorithm) and Karch and Lasagna scales, respectively. In the severity of ADRs, the most severe reactions according to the modified Hartwig-Siegel scale (level 4a in our study) were seen in 17.5 (n=12) per cent of patients, and the rest were either level 2 or 3 reactions. Nearly 92.5 (n=62) per cent of reactions were predictable according to the Rawlins and Thompson criterion. Application of the modified Schumock-Thornton scale showed that 22.4 per cent of ACS patients had preventable reactions, and the rest were not preventable. Interpretation & conclusions: The study results suggest that ADRs are relatively common among ACS patients. Most of these can be identified and assessed for causality, severity, predictability and preventability using various available scales. Diligent pharmacovigilance for identifying and assessing ADRs may help manage and mitigate morbidity associated with these in high-risk ACS patients.

20 January 2023 in Hospital Pharmacy
Verified
Journal Article
Closed access
MMManjappa Mahadevappa
Manjappa Mahadevappa
LALakshay Kumar Attri
Lakshay Kumar Attri
SCSri Harsha Chalasani
Sri Harsha Chalasani
JSJehath Syed
Jehath Syed
Dextromethorphan is a distant derivative of morphine, used as an antitussive agent indicated in standard care for various infections and respiratory conditions ranging from the common cold (rhinoviruses) to severe acute respiratory illness (SARI). Being a derivative of morphine, a natural central nervous system (CNS) depressant, dextromethorphan produces little to no action on CNS when ingested in the prescription dosage. We present a case of a 64-year-old female patient, a known case of ischemic heart disease post angioplasty and stenting to the left anterior descending artery (LAD), with heart failure with reduced ejection fraction (HFrEF), diabetes, hypertension, chronic kidney disease, and hypothyroidism who developed extrapyramidal symptoms post dextromethorphan administration. The incidence of dextromethorphan-induced dystonia is unknown, and the literature review suggests 4 case reports indicating dextromethorphan-induced dystonia, and each of those reports is a case of either accidental overdose or overdose in substance abuse disorder. No cases of these CNS side effects are described among adults with a therapeutic dose of dextromethorphan. This case report serves to sensitize the clinician about this rare occurrence.

17 July 2025 in Hospital Pharmacy
Verified
Journal Article
Closed access
KKKiran Pura Krishnamurthy
Kiran Pura Krishnamurthy
MMManjappa Mahadevappa
Manjappa Mahadevappa
BSBharath Raj Srinivasan
Bharath Raj Srinivasan
HNHimabindu Jayaprakash Narayan
Himabindu Jayaprakash Narayan
Dasatinib, a Tyrosine kinase inhibitor, functions by preventing an abnormal protein that instructs cancer cells to proliferate. It is used to treat chronic myeloid leukemia in adults who can no longer benefit from other leukemia medications, including imatinib, or those who cannot tolerate first-line medicines due to their side effects. Pleural effusion and pulmonary hypertension induced by the drug dasatinib are uncommon but serious complications that impact the pulmonary vasculature. Here, we describe a series of patients with chronic myeloid leukemia receiving dasatinib who subsequently experienced pleural effusion and pulmonary hypertension. In 2 of the 3 cases, dasatinib was used as first-line therapy, highlighting the importance of recognizing these adverse effects even when it is used upfront rather than solely after failure of first-generation TKIs. The patient’s symptoms significantly improved after stopping dasatinib and starting supportive care. This case series emphasizes the need to raise awareness among clinicians, the importance of early recognition, and the timely initiation of alternative treatment to enhance patient outcomes.